Towards tailored radiopeptide therapy.

Radojewski, Piotr; Dumont, Rebecca; Marincek, Nicolas; Brunner, Philippe; Mäcke, Helmut R; Müller-Brand, Jan; Briel, Matthias; Walter, Martin Alexander (2015). Towards tailored radiopeptide therapy. European journal of nuclear medicine and molecular imaging, 42(8), pp. 1231-1237. Springer 10.1007/s00259-015-3030-9

[img] Text
Towards Tailored Radiopeptide Therapy.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (714kB) | Request a copy

PURPOSE Somatostatin receptor-targeted radiopeptide therapy is commonly performed using single radioisotopes. We evaluated the benefits and harms of combining radioisotopes in radiopeptide therapy in patients with neuroendocrine tumor. METHODS Using multivariable-adjusted survival analyses and competing risk analyses we evaluated outcomes in patients with neuroendocrine tumor receiving (90)Y-DOTATOC, (177)Lu-DOTATOC or their combination. RESULTS (90)Y-DOTATOC plus (177)Lu-DOTATOC treatment was associated with longer survival than (90)Y-DOTATOC (66.1 vs. 47.5 months; n = 1,358; p < 0.001) or (177)Lu-DOTATOC alone (66.1 vs. 45.5 months; n = 390; p < 0.001). (177)Lu-DOTATOC was associated with longer survival than (90)Y-DOTATOC in patients with solitary lesions (HR 0.3, range 0.1 - 0.7; n = 153; p = 0.005), extrahepatic metastases (HR 0.5, range 0.3 - 0.9; n = 256; p = 0.029) and metastases with low uptake (HR 0.1, range 0.05 - 0.4; n = 113; p = 0.001). (90)Y-DOTATOC induced higher hematotoxicity rates than combined treatment (9.5% vs. 4.0%, p = 0.005) or (177)Lu-DOTATOC (9.5 vs. 1.4%, p = 0.002). Renal toxicity was similar among the treatments. CONCLUSIONS Using (90)Y and (177)Lu might facilitate tailoring radiopeptide therapy and improve survival in patients with neuroendocrine tumors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie

UniBE Contributor:

Radojewski, Piotr and Walter, Martin Alexander

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7070

Publisher:

Springer

Language:

English

Submitter:

Franziska Nicoletti

Date Deposited:

26 Feb 2016 15:36

Last Modified:

20 Mar 2018 13:23

Publisher DOI:

10.1007/s00259-015-3030-9

PubMed ID:

25792454

BORIS DOI:

10.7892/boris.76677

URI:

https://boris.unibe.ch/id/eprint/76677

Actions (login required)

Edit item Edit item
Provide Feedback